Bosch B, DeJesus MA, Poulton NC, Zhang W, Engelhart CA, Zaveri A, Lavalette S, Ruecker N, Trujillo C, Wallach JB et al..
2021.
Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.. Cell. 184(17):4579-4592.e24.
Dutta E, DeJesus MA, Ruecker N, Zaveri A, Koh E-I, Sassetti CM, Schnappinger D, Ioerger TR.
2021.
An improved statistical method to identify chemical-genetic interactions by exploiting concentration-dependence.. PLoS One. 16(10):e0257911.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..
2021.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Harnagel A, Quezada LLopez, Park SWoong, Baranowski C, Kieser K, Jiang X, Roberts J, Vaubourgeix J, Yang A, Nelson B et al..
2021.
Nonredundant functions of Mycobacterium tuberculosis chaperones promote survival under stress.. Mol Microbiol. 115(2):272-289.
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..
2021.
Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..
2021.
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..
2021.
Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Giardina SF, Valdambrini E, J Warren D, Barany F.
2021.
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance.. Curr Cancer Drug Targets. 21(4):306-325.
Chen X, Lee SKoo, Song M, Zhang T, Han MShin, Chen Y-T, Chen Z, Ma X, Tung C-H, Du Y-CNancy.
2021.
RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment.. Mol Ther Oncolytics. 23:277-287.